Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sutro Biopharma (STRO) EBITDA (2017 - 2025)

Historic EBITDA for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to -$48.5 million.

  • Sutro Biopharma's EBITDA rose 2865.18% to -$48.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$185.6 million, marking a year-over-year decrease of 4270.36%. This contributed to the annual value of -$238.5 million for FY2024, which is 16709.04% down from last year.
  • According to the latest figures from Q3 2025, Sutro Biopharma's EBITDA is -$48.5 million, which was up 2865.18% from -$3.3 million recorded in Q2 2025.
  • Over the past 5 years, Sutro Biopharma's EBITDA peaked at $43.2 million during Q4 2023, and registered a low of -$68.5 million during Q1 2025.
  • For the 5-year period, Sutro Biopharma's EBITDA averaged around -$35.6 million, with its median value being -$42.2 million (2023).
  • In the last 5 years, Sutro Biopharma's EBITDA skyrocketed by 18766.81% in 2023 and then tumbled by 25122.82% in 2024.
  • Sutro Biopharma's EBITDA (Quarter) stood at -$35.0 million in 2021, then plummeted by 40.49% to -$49.2 million in 2022, then surged by 187.67% to $43.2 million in 2023, then plummeted by 251.23% to -$65.3 million in 2024, then rose by 25.74% to -$48.5 million in 2025.
  • Its EBITDA was -$48.5 million in Q3 2025, compared to -$3.3 million in Q2 2025 and -$68.5 million in Q1 2025.